Lung Cancer最新文献_第8页

Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report 对pik3ca突变的非小细胞肺癌的不可溶性：1例报告

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2025-12-26 DOI: 10.1016/j.lungcan.2025.108890

Lei Cheng , Dongying Wang , Xueyan Zhang , Baohui Han , Hua Zhong , Wei Nie

{"title":"Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report","authors":"Lei Cheng , Dongying Wang , Xueyan Zhang , Baohui Han , Hua Zhong , Wei Nie","doi":"10.1016/j.lungcan.2025.108890","DOIUrl":"10.1016/j.lungcan.2025.108890","url":null,"abstract":"<div><h3>Introduction</h3><div><em>PIK3CA</em> mutations are oncogenic drivers in 2–4% of non-small cell lung cancers (NSCLC), often co-occurring with other drivers and conferring therapeutic resistance. This report is unique in describing the efficacy of the novel, highly selective PI3Kα inhibitor inavolisib in two heavily pre-treated patients with <em>PIK3CA</em>-mutant NSCLC harboring divergent co-drivers (<em>EGFR</em> and <em>KRAS</em>).</div></div><div><h3>Case presentation</h3><div>We present a 71-year-old male with <em>EGFR/PIK3CA</em>-mutant adenocarcinoma and brain metastases, and a 54-year-old female with <em>KRAS/PIK3CA</em>-mutant squamous cell carcinoma. Both patients reported rapid symptomatic improvement (hoarseness and shoulder pain, respectively) within two weeks of initiating inavolisib.</div></div><div><h3>Diagnosis, intervention, and outcomes</h3><div>Both patients received oral inavolisib (6 mg daily). Follow-up imaging after one month revealed significant tumor reduction. Notably, regressing intrapulmonary lesions exhibited tumor cavitation, and the male patient demonstrated a marked regression of central nervous system (CNS) metastases. The treatment was well-tolerated, with only Grade 1 oral mucositis reported.</div></div><div><h3>Conclusion</h3><div>The primary take-away lesson is that selective PI3Kα inhibition with inavolisib can induce potent systemic and intracranial responses in <em>PIK3CA</em>-mutant NSCLC, regardless of the primary oncogenic co-driver. The observed tumor cavitation suggests a potential anti-angiogenic mechanism, warranting further investigation.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108890"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145845517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis tki后治疗晚期egfr突变非小细胞肺癌的比较疗效和安全性：系统综述和网络荟萃分析

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-01-08 DOI: 10.1016/j.lungcan.2026.108914

Yuanyuan Wang , Lin Zhang , Jianhua Zhan , Ling Wen , Xinyuan Zhao , Haishuang Sun , Xueyuan Chen , Yaxiong Zhang , Gang Chen , Yuanyuan Zhao , Yan Huang , Wenfeng Fang , Li Zhang , Dongchen Sun , Yunpeng Yang

{"title":"Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis","authors":"Yuanyuan Wang , Lin Zhang , Jianhua Zhan , Ling Wen , Xinyuan Zhao , Haishuang Sun , Xueyuan Chen , Yaxiong Zhang , Gang Chen , Yuanyuan Zhao , Yan Huang , Wenfeng Fang , Li Zhang , Dongchen Sun , Yunpeng Yang","doi":"10.1016/j.lungcan.2026.108914","DOIUrl":"10.1016/j.lungcan.2026.108914","url":null,"abstract":"<div><h3>Background</h3><div>Despite the availability of several validated therapies, the optimal second-line regimen for <em>EGFR</em>-mutant non-small cell lung cancer (NSCLC) after tyrosine kinase inhibitor (TKI) failure remains uncertain.</div></div><div><h3>Methods</h3><div>The protocol was registered in PROSPERO (CRD420251157131). We systematically searched MEDLINE, Embase, CENTRAL, and conference proceedings (to Oct 20, 2025) for phase III randomized controlled trials (RCTs). A Bayesian network <em>meta</em>-analysis was performed. The primary outcome was progression-free survival (PFS). Secondary outcomes included overall survival (OS) and the incidence of grade ≥3 treatment-related adverse events (TRAEs).</div></div><div><h3>Results</h3><div>Eleven RCTs (3,650 patients, seven regimens) were included. Compared to chemotherapy, sacituzumab tirumotecan (SacTMT), amivantamab plus chemotherapy (Chemo-Ami), and chemo-immunotherapy plus anti-angiogenic agent (Chemo-IO-anti-VEGF) demonstrated superior PFS (HR 0.49, 0.48, 0.53, respectively) and OS (HR 0.60, 0.73, 0.83, respectively). SacTMT also significantly improved OS over chemo-immunotherapy (HR 0.68, 95 % CrI 0.48 to 0.95). Regarding safety, Chemo-Ami carried higher grade ≥3 TRAEs risk (OR 2.83, 95 % CrI 1.01 to 7.90) versus chemotherapy, while SacTMT and Chemo-IO-anti-VEGF demonstrated toxicity comparable to chemotherapy.</div></div><div><h3>Conclusions</h3><div>SacTMT, Chemo-Ami, and Chemo-IO-anti-VEGF offer superior efficacy over chemotherapy for <em>EGFR</em>-mutant NSCLC after TKI progression. SacTMT and Chemo-IO-anti-VEGF may have more favorable safety profiles than Chemo-Ami. This comparative evidence helps to inform clinical decision-making.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108914"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis”. [Lung Cancer 205 (2025) 108626] “按年龄、性别和形态划分的肺癌发病率和死亡率的全球趋势和预测：基于自助的分析”的勘误表。[肺癌205(2025)108626]。

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-01-11 DOI: 10.1016/j.lungcan.2026.108909

Jinto Edakkalathoor George , Preethi Sara George , Jagathnath K.M. Krishna , Aleyamma Mathew

引用次数: 0

Is sublobar resection a valid option for radiologically pure-solid clinical stage IA non-small cell lung cancer?: insights from real-world data and current status 肺叶下切除术是放射学纯实性临床IA期非小细胞肺癌的有效选择吗？：来自真实世界数据和当前状态的见解

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2025-12-23 DOI: 10.1016/j.lungcan.2025.108886

Dong Woog Yoon , Sumin Shin , Chu Hyun Kim , Yeong Jeong Jeon , Junghee Lee , Seong Yong Park , Yong Soo Choi , Jong Ho Cho , Hong Kwan Kim , Ho Yun Lee

{"title":"Is sublobar resection a valid option for radiologically pure-solid clinical stage IA non-small cell lung cancer?: insights from real-world data and current status","authors":"Dong Woog Yoon , Sumin Shin , Chu Hyun Kim , Yeong Jeong Jeon , Junghee Lee , Seong Yong Park , Yong Soo Choi , Jong Ho Cho , Hong Kwan Kim , Ho Yun Lee","doi":"10.1016/j.lungcan.2025.108886","DOIUrl":"10.1016/j.lungcan.2025.108886","url":null,"abstract":"<div><h3>Objectives</h3><div>We aimed to evaluate the oncologic outcomes of sublobar resection (SLR) compared with lobectomy in patients with radiologically pure-solid stage IA non–small cell lung cancer (NSCLC).</div></div><div><h3>Methods</h3><div>We retrospectively reviewed 363 patients with clinical stage IA pure-solid NSCLC who underwent curative-intent resection between 2018 and 2020. Patients were divided into SLR (n = 60) and lobectomy (n = 303) groups. Kaplan–Meier analysis was used to estimate overall survival (OS) and recurrence-free survival (RFS), and Cox regression identified prognostic factors. Subgroup analyses were performed for stage IA2 and IA3 patients.</div></div><div><h3>Results</h3><div>In the overall cohort, the SLR group had significantly worse 5-year OS (75.5 % vs. 93.3 %, p < 0.01) and RFS (58.3 % vs. 77.4 %, p < 0.01) compared with lobectomy. In stage IA2, OS was comparable (87.2 % vs. 91.7 %, p = 0.1), but RFS was inferior after SLR (65.9 % vs. 81.2 %, p = 0.02). In stage IA3, both OS (54.3 % vs. 94.4 %, p < 0.01) and RFS (40.6 % vs. 74.9 %, p < 0.01) were markedly worse after SLR. Segmentectomy showed outcomes similar to lobectomy in IA2 but was inferior in IA3, whereas wedge resection was consistently associated with poor survival.</div></div><div><h3>Conclusions</h3><div>Lobectomy remains the standard surgical procedure for pure-solid stage IA NSCLC, particularly IA3 disease. Segmentectomy may be considered in carefully selected IA2 patients, while it is advisable to avoid wedge resection. These findings emphasize the importance of selecting the most appropriate patients for SLR and support the need for prospective validation.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108886"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145882761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

69 Assessing the Reliability of CT in Predicting Malignancy of Ground Glass and Subsolid Lung Nodules 69 CT对肺磨玻璃结节和实下结节恶性预测的可靠性评估

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-02-27 DOI: 10.1016/j.lungcan.2026.109018

Jeffrey Li Voon Chong , Lynne Armstrong

引用次数: 0

88 Charting New Paths: A DGH's experience with Advanced Navigational Bronchoscopy in Lung Cancer Diagnosis 新路径：DGH在肺癌诊断中的先进导航支气管镜经验

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-02-27 DOI: 10.1016/j.lungcan.2026.109037

Deep Babla , Eugene Ming Yang Yap , Hathija Siddique , Mutiu Adamo , Ryan Dhunnookchand , Samir Alwan , Farah Din , Tom Newsom-Davis , Piers Dixey , Orhan Orhan , Dexter Wiseman

引用次数: 0

44 Early Experience of Managing the Patient Pathway in the Neoadjuvant Era: Surgical Outcomes from a Single Centre District General Hospital 新辅助时代患者路径管理的早期经验：来自单一中心地区综合医院的手术结果

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-02-27 DOI: 10.1016/j.lungcan.2026.108993

James Palmer , Ashok Kar , Tathagata Das , Vicky Athey

引用次数: 0

45 An audit of the “Abnormal Chest X-Raywalk-in service” at Guy's and St Thomas’ NHS Foundation Trust 45对盖伊和圣托马斯NHS基金会信托的“异常胸部x光检查服务”的审计

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-02-27 DOI: 10.1016/j.lungcan.2026.108994

Erin Doherty , Poppy Denniston , Victoria Taylor , Nora Van Der Stelt , Owais Kadwani

引用次数: 0

74 Heterogeneity and High Cancer Conversion in a Real-World Pulmonary Nodule Cohort: Implications for UK Surveillance Practice 真实世界肺结节队列的异质性和高癌症转化：对英国监测实践的启示

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-02-27 DOI: 10.1016/j.lungcan.2026.109023

Prashanthi Ratnakumar , Jane Derbyshire , Katie Morris , John Burchill , Konstantinos Callis , Richard Lee , Erik Mayer , Jennifer Quint , Susannah Bloch

引用次数: 0

76 BTOG Large Cell Neuroendocrine Carcinoma Special Interest Group: Interim feasibility analysis froma national multicentre digital pathology review of diagnostic consensus 76 BTOG大细胞神经内分泌癌特别兴趣组：来自诊断共识的国家多中心数字病理综述的中期可行性分析

IF 4.4 2区医学

Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-02-27 DOI: 10.1016/j.lungcan.2026.109025

Rebecca Ward , Alex Haragan , Danielle Bury , David Moore , David Dorward , Lauren D'sa , Fiona Roberts , Slaveya Yancheva , Leena Joseph , Kirsty Lloyd , Filomena Medeiros , Karen Shackcloth , Colin Lindsay , Anshuman Chaturvedi

引用次数: 0